Two new national surveys on the use of cannabis for the treatment of patients with inflammatory bowel disease (IBD) have been launched in Australia. The anonymous surveys — one designed for patients and another for IBD specialists across the country — are meant to evaluate the impact of cannabis-based medications on IBD patients' work, productivity, overall quality of life, and medication use. IBD comprises a group of autoimmune disorders, including Crohn’s disease and ulcerative colitis, that cause inflammation of the gastrointestinal (GI) tract. As a result, patients experience bouts of abdominal pain and diarrhea, often accompanied by weight loss and rectal bleeding, which pose a significant burden to their overall quality of life. For this reason, many patients turn to cannabis-based medications to seek relief from their flare-ups and to better manage their symptoms. In 2016, the Lambert Initiative for Cannabinoid Therapeutics, created by the University of Sydney in Australia, launched the first survey, called the Cannabis as Medicine Survey (CAMS-16), to assess the impact of medicinal cannabis on the lives of Australian patients.